Results 41 to 50 of about 3,046,243 (224)

Essential thrombocythemia: 2024 update on diagnosis, risk stratification, and management

American journal of hematology/oncology
Essential thrombocythemia is a Janus kinase 2 (JAK2) mutation‐prevalent myeloproliferative neoplasm characterized by clonal thrombocytosis; clinical course is often indolent but might be interrupted by thrombotic or hemorrhagic complications ...
A. Tefferi, A. Vannucchi, T. Barbui
semanticscholar   +1 more source

Essential thrombocythemia: a rare disease in childhood

Revista Brasileira de Hematologia e Hemoterapia, 2013
Essential thrombocythemia is an acquired myeloproliferative disorder characterized by the proliferation of megakaryocytes in bone marrow, leading to a persistent increase in the number of circulating platelets and thus increasing the risk for thrombotic ...
Julia Maimone Beatrice, Marlene Pereira Garanito   +1 more
doaj   +1 more source

The Essential Thrombocythemia in 2020: What We Know and Where We Still Have to Dig Deep

Clinical Medicine Insights Blood Disorders, 2020
The Essential Thrombocythemia is a Chronic Philadelphia-negative Myeloproliferative Neoplasm characterized by a survival curve that is only slightly worse than that of age- and sex-adjusted healthy population.
V. Accurso, M. Santoro, S. Mancuso, M. Napolitano, M. Carlisi, Marta Mattana, C. Russo, A. Di Stefano, Davide Sirocchi, S. Siragusa   +9 more
semanticscholar   +1 more source

One thousand patients with essential thrombocythemia: the Florence-CRIMM experience

Blood Cancer Journal
We describe 1000 patients with essential thrombocythemia seen at the Center Research and Innovation of Myeloproliferative Neoplasms (CRIMM), Florence, Italy, between 1980 and 2023: median age 59 years (18–95), females 65%, JAK2/CALR/MPL-mutated 66%/19%/4%
G. G. Loscocco, F. Gesullo, Giulio Capecchi, A. Atanasio, C. Maccari, F. Mannelli, A. Vannucchi, P. Guglielmelli   +7 more
semanticscholar   +1 more source

A risk of essential thrombocythemia in carriers of constitutional CHEK2 gene mutations

Haematologica, 2012
Germline mutations of the CHEK2 gene have been reported in some myeloid and lymphoid malignancies, but their impact on development of essential thrombocythemia has not been studied.
Hanna Janiszewska, Aneta Bąk, Maria Pilarska, Marta Heise, Anna Junkiert-Czarnecka, Małgorzata Kuliszkiewicz-Janus, Małgorzata Całbecka, Bożena JaŸwiec, Dariusz Wołowiec, Kazimierz Kuliczkowski, Olga Haus   +10 more
doaj   +1 more source

CALR mutation burden in essential thrombocythemia and disease outcome.

Blood
Among 281 patients with essential thrombocythemia and calreticulin mutation, we found a variant allele frequency of >60% to be associated with significantly shortened myelofibrosis-free survival, mostly apparent with CALR type-1 and CALR type ...
P. Guglielmelli, N. Szuber, N. Gangat, Giulio Capecchi, C. Maccari, M. Harnois, Omer S Karrar, Maymona G. Abdelmagid, M. Balliu, Elena Nacca, A. Atanasio, Ilaria Sestini, Audrey Désilets, G. G. Loscocco, G. Rotunno, Lambert Busque, A. Tefferi, A. Vannucchi   +17 more
semanticscholar   +1 more source

Clonal analyses reveal associations of JAK2V617F homozygosity with hematologic features, age and gender in polycythemia vera and essential thrombocythemia

Haematologica, 2013
Subclones homozygous for JAK2V617F are more common and larger in patients with polycythemia vera compared to essential thrombocythemia, but their role in determining phenotype remains unclear.
Anna L. Godfrey, Edwin Chen, Francesca Pagano, Yvonne Silber, Peter J. Campbell, Anthony R. Green   +5 more
doaj   +1 more source

A case of essential thrombocythemia and ankylosing spondylitis treated with a combination of anagrelide, disease-modifying antirheumatic drugs, and etanercept [PDF]

Srpski Arhiv za Celokupno Lekarstvo, 2016
Introduction. A high platelet count, or thrombocytosis, is either a reactive process or a result of a myeloproliferative disorder. Ankylosing spondylitis is a chronic inflammatory rheumatic disease affecting the spine and sometimes peripheral ...
Zeremski Vanja, Savić Aleksandar, Ilić Tatjana, Milošević Ivana, Maksimović Marina, Vučković Biljana   +5 more
doaj   +1 more source

Population Pharmacokinetics and Exposure–Response Analyses of Momelotinib, Its Active Metabolite (M21), and Total Active Moiety in Myelofibrosis

Clinical Pharmacology &Therapeutics, EarlyView.
Momelotinib, a Janus kinase (JAK) 1/JAK2/activin A receptor type 1 inhibitor, is approved for the treatment of myelofibrosis with anemia. These analyses characterized the population pharmacokinetics of momelotinib and its active metabolite M21 following administration of the commercial tablet formulation in patients with myelofibrosis from phase II/III
Benjamin Rich, Meenakshi Srinivasan, Yu Liu Ho, Sandra A.G. Visser, Geraldine Ferron‐Brady, Georgios Vlasakakis   +5 more
wiley   +1 more source

Neurological disorders in essential thrombocythemia

Haematologica, 2011
Patients with essential thrombocythemia often complain of various subjective neurological symptoms. This prospective study aims to assess their incidence and response to therapy.
Segolene Billot, Eirini G. Kouroupi, Johan Le Guilloux, Bruno Cassinat, Caroline Jardin, Thierry Laperche, Pierre Fenaux, Antoine F. Carpentier, Jean-Jacques Kiladjian   +8 more
doaj   +1 more source